ストックスクリーナーアプリを入手
30.04
1.04%
0.31
Roivant Sciences Ltd (ROIV) 最新ニュース
Te Ahumairangi Investment Management Ltd Decreases Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Guggenheim and Citi Raise Roivant Sciences Price Targets After EarningsEarnings Surprise Score - newsline.com
Clearbridge Investments LLC Boosts Stock Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
Bank of New York Mellon Corp Has $63 Million Stock Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
Transcript : Roivant Sciences Ltd. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11 - marketscreener.com
Roivant gains after mid-stage trial data for Immunovant’s main asset - MSN
Guggenheim Remains Bullish on Roivant Sciences Ltd. (ROIV) - Insider Monkey
ROIV: Brepocitinib leads a robust pipeline targeting rare diseases, with strong data and launch plans - TradingView
ROIV: Late-stage pipeline advances in rare diseases and immunology, with strong financial flexibility - TradingView
TD Asset Management Inc Purchases 235,176 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant anticipates $950M Moderna payment in July as it outlines 2H 2026 mosliciguat and IMVT-1402 readouts - MSN
588,400 Shares in Roivant Sciences Ltd. $ROIV Purchased by ING Groep NV - MarketBeat
Roivant Sciences Ltd. (ROIV) Stock Analysis: A Biotech Powerhouse with a 36.60% Potential Upside - DirectorsTalk Interviews
CenterBook Partners LP Purchases 364,390 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
10 Best Healthcare Stocks to Buy with Highest Upside Potential - Insider Monkey
Goldman Sachs Group Inc. Buys 8,621,567 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences’ $2.25 Billion Moderna Settlement: Can Pipeline Momentum Follow? - Smartkarma
Precision Trading with Roivant Sciences Ltd. (ROIV) Risk Zones - Stock Traders Daily
WINTON GROUP Ltd Has $7.08 Million Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Norges Bank Makes New Investment in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ROIV: Late-stage pipeline advances and imminent DM launch set up multiple catalysts for the year - TradingView
Legal & General Group Plc Has $12.80 Million Stock Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
BNP Paribas Financial Markets Has $49.79 Million Stock Position in Roivant Sciences Ltd. $ROIV - MarketBeat
ROIV Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Did Roivant’s (ROIV) Profitable Quarter and $982 Million Shelf Filing Just Reframe Its Capital Strategy? - simplywall.st
Roivant Sciences Ltd. (ROIV) Stock Report: Analyzing The 30.18% Potential Upside - DirectorsTalk Interviews
Roivant shares climb on earnings beat despite revenue shortfall (ROIV) - MSN
Roivant Sciences (ROIV) Valuation After Strong IMVT-1402 Data And Late Stage Pipeline Momentum - simplywall.st
Roivant Sciences Ltd.Common Shares (NQ: ROIV - FinancialContent
J.P. Morgan Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $40 - Moomoo
ROIV Maintained by Guggenheim -- Price Target Raised to $36.00 - GuruFocus
Roivant Sciences Insider Sold Shares Worth $6,054,000, According to a Recent SEC Filing - Moomoo
Technical Reactions to ROIV Trends in Macro Strategies - Stock Traders Daily
Assessing Roivant Sciences (ROIV) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Roivant Shelf Plan Raises Questions On Dilution And Pipeline Funding - simplywall.st
TD Cowen Raises its Price Target on Roivant Sciences (ROIV) - Insider Monkey
Litigation Windfall Driving Roivant Sciences’ Profit Swing Might Change The Case For Investing In Roivant Sciences (ROIV) - Yahoo Finance
Today's Analyst Rating | Roivant Sciences Price Target Raised to $31.5 by BofA Securities, UBS Downgrades Millicom International Cellular to Hold - Moomoo
Roivant Sciences Ltd. (ROIV) - DirectorsTalk Interviews
Should Roivant’s One‑Off Driven Profitability Shift Require Action From Roivant Sciences (ROIV) Investors? - Sahm
Roivant Sciences (ROIV) Slips Nearly 3% as Shares Test Key Support ZoneDealer Delta - thelegaladvocate.com
[Form 4] Roivant Sciences Ltd. Insider Trading Activity - Stock Titan
A Quick Look at Today's Ratings for Roivant Sciences(ROIV.US), With a Forecast Between $34 to $42 - Moomoo
ROIV Stock Price Prediction 2025-2026 | Roivant Sciences Ltd Forecast - 24/7 Wall St.
TD Cowen raises Roivant Sciences stock price target to $41 on trial data - Investing.com Australia
H.C. Wainwright reiterates Roivant Sciences stock rating on IMVT-1402 data By Investing.com - Investing.com South Africa
ROIV Maintained by Citigroup -- Price Target Raised to $42.00 - GuruFocus
0.65%
0.76%
大文字化:
|
ボリューム (24 時間):